6 Years Out, Nivo–Ipi Looks Solid in NSCLC

According to the latest update from CheckMate 227 Part 1, at 6 years' minimum follow-up, nivolumab combined with ipilimumab continues to outperform chemotherapy up front for advanced non-small cell lung cancer in terms of overall survival. Dual immune checkpoint inhibition induced greater tumor shrinkage, and these deep responses strongly correlated with long-term OS benefit.